Page 19 - 《中国药房》2024年3期
P. 19

2017,83(10):2195-2204.                              tumor[J]. Chin J Gastrointest Surg,2019,22(9):848-855.
          [53]  ZHANG Y J,QIANG S P,YU Z,et al. LC-MS-MS deter‐  [62]  WIDMER N,DECOSTERD L A,CSAJKA C,et al. Ima‐
              mination of imatinib and N-desmethyl imatinib in human   tinib  plasma  levels:correlation  with  clinical  benefit  in
              plasma[J]. J Chromatogr Sci,2014,52(4):344-350.     GIST patients[J]. Br J Cancer,2010,102(7):1198-1199.
          [54]  MIURA M,TAKAHASHI N,SAWADA K I. Quantitative   [63]  DELBALDO  C, CHATELUT  E, RÉ  M, et  al.
              determination  of  imatinib  in  human  plasma  with  high-  Pharmacokinetic-pharmacodynamic  relationships  of  ima‐
              performance liquid chromatography and ultraviolet detec‐  tinib  and  its  main  metabolite  in  patients  with  advanced
              tion[J]. J Chromatogr Sci,2011,49(5):412-415.       gastrointestinal stromal tumors[J]. Clin Cancer Res,2006,
          [55]  董馨蔚,蒋刚,马松涛,等. 二维液相色谱法同时测定人                        12(20 Pt 1):6073-6078.
              血浆中伊马替尼及其代谢产物浓度的方法学研究[J]. 肿                    [64]  WANG Q,JIANG Z P,YU E Q,et al. Population pharma‐
              瘤预防与治疗,2021,34(10):918-925.                         cokinetic and pharmacogenetics of imatinib in Chinese pa‐
              DONG X W,JIANG G,MA S T,et al. Simultaneous de‐     tients  with  chronic  myeloid  leukemia[J].  Pharmacogeno-
              termination of imatinib mesylate and its metabolites in hu‐  mics,2019,20(4):251-260.
              man plasma by two-dimensional liquid chromatography:a   [65]  GSCHWIND H P,PFAAR U,WALDMEIER F,et al. Me‐
              methodological  study[J].  J  Cancer  Contr  Treat,2021,34  tabolism  and  disposition  of  imatinib  mesylate  in  healthy
              (10):918-925.                                       volunteers[J].  Drug  Metab  Dispos,2005,33(10):1503-
          [56]  孔滢,刘红,彭洪薇,等. 二维液相色谱法同时测定人血                        1512.
              浆中伊马替尼及去甲伊马替尼药物浓度及临床应用[J].                     [66]  中国药学会医院药学专业委员会. 治疗药物监测结果解
              中国现代应用药学,2022,39(17):2229-2235.                     读专家共识[J]. 中国医院药学杂志,2020,40(23):2389-
              KONG Y,LIU H,PENG H W,et al. Simultaneous deter‐    2395.
              mination of imatinib and N-desmethyl imatinib in human   Professional  Committee  of  Hospital  Pharmacy,Chinese
              plasma by two-dimensional liquid chromatography and its   Pharmaceutical Association. The expert consensus on the
              clinical application[J]. Chin J Mod Appl Pharm,2022,39  interpretation  of  therapeutic  drug  monitoring[J].  Chin  J
              (17):2229-2235.                                     Hosp Pharm,2020,40(23):2389-2395.
          [57]  ZHOU Y,LAI J L,QIU F,et al. Development and valida‐  [67]  GOTTA  V,WIDMER  N,MONTEMURRO  M,et  al.
              tion  of  an  HPLC-UV  method  for  routine  trough  plasma   Therapeutic drug monitoring of imatinib:Bayesian and al‐
              concentration  monitoring  of  imatinib  in  Chinese  patients   ternative methods to predict trough levels[J]. Clin Pharma‐
              with gastrointestinal stromal tumor[J]. J Chin Pharm Sci,  cokinet,2012,51(3):187-201.
              2020,29(9):637-648.                            [68]  JANSSEN  J  M,DORLO  T  P  C,BEIJNEN  J  H,et  al.
          [58]  张玉,缪丽燕. 胃肠间质瘤靶向药物的治疗药物监测中                         Evaluation of extrapolation methods to predict trough con‐
              国专家共识[J]. 中国医院药学杂志,2021,41(20):2041-                centrations  to  guide  therapeutic  drug  monitoring  of  oral
              2049.                                               anticancer  drugs[J].  Ther  Drug  Monit,2020,42(4):
              ZHANG  Y,MIAO  L  Y.  Chinese  expert  consensus  on   532-539.
              therapeutic drug monitoring of targeted drugs for gastroin‐  [69]  ZHOU  Y,WU  X  Y,LI  J,et  al.  Clinical  and  economic
              testinal  stromal  tumor[J].  Chin  J  Hosp  Pharm,2021,41  benefits  of  a  pharmacist  in  a  multidisciplinary  team  for
              (20):2041-2049.                                     Chinese  outpatients  with  gastrointestinal  stromal  tumors
          [59]  DEMETRI G D,WANG Y F,WEHRLE E,et al. Imatinib     [J]. J Chin Pharm Sci,2021,30(7):598-605.
              plasma  levels  are  correlated  with  clinical  benefit  in  pa‐  [70]  张威,张宇晴,陆进,等. 医疗机构药事管理与药学服务
              tients with unresectable/metastatic gastrointestinal stromal   团体标准体系设计及构建[J]. 医药导报,2023,42(10):
              tumors[J]. J Clin Oncol,2009,27(19):3141-3147.      1455-1459.
          [60]  TERANISHI  R,TAKAHASHI  T,NISHIDA  T,et  al.      ZHANG W,ZHANG Y Q,LU J,et al. Design and con‐
              Plasma trough concentration of imatinib and its effect on   struction  of  group  standard  system  framework  for  phar‐
              therapeutic  efficacy  and  adverse  events  in  Japanese  pa‐  macy administration and pharmacy practice in healthcare
              tients  with  GIST[J].  Int  J  Clin  Oncol,2023,28(5):  institutions[J]. Her Med,2023,42(10):1455-1459.
              680-687.                                       [71]  MORISKY  D  E,ANG A,KROUSEL-WOOD  M,et  al.
          [61]  WAN W Z,ZHANG P,ZENG X Y,et al. Analysis of ima‐  Predictive validity of a medication adherence measure in
              tinib  trough  concentration  at  steady  state  in  adjuvant   an outpatient setting[J]. J Clin Hypertens,2008,10(5):
              therapy of patients with high risk gastrointestinal stromal   348-354.


          中国药房  2024年第35卷第3期                                                 China Pharmacy  2024 Vol. 35  No. 3    · 269 ·
   14   15   16   17   18   19   20   21   22   23   24